ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 233 filers reported holding ROYALTY PHARMA PLC in Q2 2021. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,159,455 | -13.3% | 595,411 | -1.8% | 0.02% | -3.8% |
| Q2 2023 | $18,637,416 | -12.7% | 606,292 | +2.3% | 0.03% | -18.8% |
| Q1 2023 | $21,345,289 | -9.2% | 592,431 | -0.5% | 0.03% | -13.5% |
| Q4 2022 | $23,519,024 | +0.2% | 595,117 | +1.9% | 0.04% | -7.5% |
| Q3 2022 | $23,467,000 | -5.2% | 584,051 | -0.8% | 0.04% | +2.6% |
| Q2 2022 | $24,751,000 | +12.1% | 588,755 | +3.9% | 0.04% | +34.5% |
| Q1 2022 | $22,070,000 | -7.2% | 566,475 | -5.1% | 0.03% | +3.6% |
| Q4 2021 | $23,785,000 | +50.5% | 596,869 | +36.5% | 0.03% | +40.0% |
| Q3 2021 | $15,800,000 | -32.5% | 437,188 | -23.5% | 0.02% | -31.0% |
| Q2 2021 | $23,421,000 | -6.5% | 571,384 | -0.5% | 0.03% | -12.1% |
| Q1 2021 | $25,049,000 | +153.6% | 574,260 | +191.0% | 0.03% | +135.7% |
| Q4 2020 | $9,879,000 | +58.9% | 197,373 | +33.5% | 0.01% | +40.0% |
| Q3 2020 | $6,219,000 | – | 147,831 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |